Galinpepimut-S is a Subunit Vaccine owned by SELLAS Life Sciences Group, and is involved in 14 clinical trials, of which 6 were completed, and 8 are ongoing.

Galinpepimut-S elicits anti-neoplastic properties by stimulating the immune system. The therapeutic candidate induces a WT1-specific cytotoxic T-lymphocyte response against WT1 expressing cells, thereby resulting in cell lysis and destruction of the cancer cells expressing WT1. The therapeutic candidate by killing the cancer cells may check the progression of disease.

The revenue for Galinpepimut-S is expected to reach a total of $692m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Galinpepimut-S NPV Report.

Galinpepimut-S was originated by Memorial Sloan Kettering Cancer Center and is currently owned by SELLAS Life Sciences Group.

Galinpepimut-S Overview

Galinpepimut-S is under development for the treatment of acute myelocytic leukemia (AML), acute lymphocytic leukemia (ALL),  lung cancer, solid tumor, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, colorectal cancer, triple-negative breast cancer, small-cell lung cancer, fallopian tube or primary peritoneal cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, diffuse large B-cell lymphoma, follicular lymphoma and myelodysplastic syndrome. It is formulated as an emulsion or solution and administered subcutaneously and parenterally. It is a synthetic peptide vaccine consisting of the immunogenic amino acids of the human Wilms tumor protein-1 peptides which include WT-1 A1, WT-1 122 long, WT-1 427 long and WT-1 331 long. The therapeutic candidate targets Wilms tumor protein 1 (WT1). It was also under development for the treatment of chronic myeloid leukemia (CML) and glioblastoma multiforme.

SELLAS Life Sciences Group Overview

SELLAS Life Sciences Group (SELLAS), formerly Galena Biopharma, develops novel cancer immunotherapeutics for multiple cancer treatments. Its pipeline product candidates include galinpepimut-S (GPS), a wilms tumor1 (WT1) protein-targeting synthetic heteroclitic epitope immunotherapeutic antigen used for the treatment of acute myeloid leukemia, ovarian cancer, malignant pleural mesothelioma, multiple myeloma and solid tumors; and Nelipepimut-S, a vaccine derived from the human epidermal growth factor 2 or HER2 protein for the prevention of breast cancer and gastric carcinomas. The company collaborates with Memorial Sloan Kettering Cancer Center (MSKCC), National Cancer Institute (NCI) and The University of Texas M.D. Anderson Cancer Center (MDACC) for conducting clinical trials targeting multiple cancer indications. SELLAS is headquartered in New York City, New York, the US.

The company reported revenues of (US Dollars) US$7.6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$1.9 million in FY2020. The operating loss of the company was US$25.3 million in FY2021, compared to an operating loss of US$17 million in FY2020. The net loss of the company was US$20.7 million in FY2021, compared to a net loss of US$16.8 million in FY2020.

Quick View – Galinpepimut-S

Report Segments
  • Innovator
Drug Name
  • Galinpepimut-S
Administration Pathway
  • Parenteral
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.